Innova BioSciences Introduces InnovaGOLD Nanoparticles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innova BioSciences Introduces InnovaGOLD Nanoparticles
New ultra-high quality gold nanoparticles simplify assay development and improve the sensitivity of immunoassays.


Innova Biosciences, a specialist provider of bioconjugation products and services, has launched InnovaGOLD, a new range of ultra-high quality gold nanoparticles. According to the company, InnovaGOLD offers improved sensitivity, stability and reproducibility in immunoassays compared with other commercially available gold colloids.

Gold nanoparticles are used in applications such as lateral flow point-of-care assays, microscopy, flow cytometry, Raman spectroscopy and dynamic light scattering. In contrast with other gold nanoparticle products, the InnovaGOLD particles have a highly consistent spherical shape, and demonstrate a high efficiency for antibody binding leading to maximum sensitivity.

The InnovaGOLD range has been developed to complement existing products in Innova’s gold nanoparticle range, which includes InnovaCoat GOLD for scientists using large volumes of nanoparticles for the manufacture of sensitive diagnostic tests. The InnovaGOLD range is available in high concentrations, to simplify assay development. 

"The combination of the InnovaCoat GOLD and the new InnovaGOLD product range is unique and provides customers with a range of options to optimise their use of gold in immunoassay systems and other applications, with the added benefit of Innova’s extensive experience in bioconjugation,” said Dr Nick Gee, CEO of Innova in a press statement.

Further information about InnovaGOLD can be found at www.innovabiosciences.com/InnovaGOLD-gold-nanoparticles.html

Source: Innova

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here